Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
Cytotoxic T-lymphocyte associated protein 4 (CTLA-4), encoded by the CTLA4 gene, is a transmembrane glycoprotein receptor stored predominantly intracellularly and transiently transported to the cell surface after T-cell activation in activated T cells and regulatory T cells (Tregs).
Cytotoxic T-lymphocyte associated protein 4 (CTLA-4), encoded by the CTLA4 gene, is a transmembrane glycoprotein receptor stored predominantly intracellularly and transiently transported to the cell surface after T-cell activation in activated T cells and regulatory T cells (Tregs). It functions as a critical negative regulator of T cell-mediated immune responses, acting as an inhibitory checkpoint that restrains excessive immune activation and maintains peripheral self-tolerance. CTLA-4 competes with the co-stimulatory receptor CD28 for binding to B7 ligands (CD80 and CD86) on antigen-presenting cells such as dendritic cells, but with far greater affinity, enabling it to outcompete CD28 and dampen T cell activation signals. This competitive inhibition is central to immune homeostasis: CTLA-4 signaling limits the proliferation and effector function of cytotoxic T cells while reinforcing the suppressive activity of regulatory T cells, thereby preventing autoimmunity.
The biological significance of CTLA-4 extends beyond immune tolerance to encompass a central role in tumor immune evasion. Because tumors can exploit CTLA-4-mediated suppression to escape immune surveillance, blocking this checkpoint has become a cornerstone of cancer immunotherapy. The anti-CTLA-4 monoclonal antibody ipilimumab was the first immune checkpoint inhibitor approved by regulatory agencies, establishing proof-of-concept for the broader class of checkpoint inhibitor therapies. CTLA-4 acts in close functional concert with other inhibitory receptors including PD-1, LAG3, TIM-3, and TIGIT, and its interplay with the PD-1/PD-L1 pathway has become a major axis of contemporary immuno-oncology research.
Where the papers sit
19 papers from the last 6 months study Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) directly · updated from PubMed 16 Nov 2026
Study type 1 clinical trial · 3 observational · 4 human data · 11 preclinical
Themes 4 themes · 1 paradigm shift · 1 new direction
-
Cancer Immunotherapy
Combination immunotherapy is moving beyond PD-1 or CTLA-4 blockade alone toward chemotherapy, oncolytic viruses, macrophage reprogramming and targeted checkpoint inhibitors. Benefit is repeatedly tied to expanded effector CD8+ T-cell clones, IL-18R1+ CD8+ cells and tumor-microenvironment remodeling. Transcriptomic and immune signatures are being used to identify responders, including in microsatellite-stable colorectal cancer and melanoma. Small-molecule CTLA-4 inhibition and mRNA lipid nanoparticles remain emerging approaches, with survival benefit and durability still unresolved.
9 papers · 47.4%
-
Cytokine Cancer Immunotherapy
Immune-cold solid tumors are being approached with cytokine support and combinations that pair checkpoint inhibition with in situ vaccination or low-dose targeted radionuclide therapy. IL-2 studies focus on Treg/CTLA-4 balance, while plasma cytokines and circulating microRNA signatures are being evaluated as markers in head and neck and breast cancer. The recurring goal is to convert immune phenotype into treatment selection and response. Clinical reproducibility and the durability of these biomarker-guided strategies remain open.
4 papers · 21.1%
-
Checkpoint Toxicity and Safety
Checkpoint therapy is increasingly defined by the need to prevent or manage immune-related toxicity, especially concurrent myasthenia gravis and myocarditis. Plasma exchange appears as a rescue strategy in severe cases, while rogue regulatory T cells offer a possible mechanism for immune dysregulation. Anti-CTLA-4 engineering is shifting toward retaining antitumor activity while reducing harmful immune activation. The evidence remains centered on rare, serious events rather than definitive toxicity predictors.
3 papers · 15.8%
-
Others — Immune Regulation across Diseases
CTLA-4 regulation appears in distinct settings, from Th1 control during latent cryptococcosis to altered CTLA-4 expression and viral load during PRRSV-1 infection. A separate clinical genetics study tests CTLA4 and LAG3 polymorphisms as correlates of outcome after BCMA CAR-T therapy in multiple myeloma. These findings share interest in T-cell restraint but do not establish a common disease mechanism or therapeutic direction. The cluster therefore remains exploratory rather than converging on one intervention.
3 papers · 15.8%
CTLA-4-associated immune regulation is not uniformly suppressive but can support protective or antitumor inflammation
Latent pulmonary Cryptococcus neoformans infection in mice and immune checkpoint inhibitor-induced inflammatory arthritis show that CTLA-4-associated regulatory programs do not invariably represent failed immunity. During latent cryptococcosis, CTLA-4 expression occurs within heterogeneous CD4 T-cell responses that include protective Th1-like activity, and CTLA-4-regulated responses contribute to fungal control; in checkpoint inhibitor–associated arthritis, blockade is accompanied by atypical regulatory T cells with reduced suppressive capacity and a Th17-like proinflammatory phenotype, whose abundance correlates with more severe arthritis but improved cancer outcomes. Together, these findings replace a uniformly inhibitory interpretation with a context-dependent one in which CTLA-4-related regulation can participate in protective host defense or beneficial antitumor inflammation 42484324Jul 42383349Jul.
CTLA-4 blockade can control glioma through a distal antibody-producing B-cell response
Glioma in mice provides a role for CTLA-4 blockade outside the set’s predominant T-cell-centered mechanisms. Anti-CTLA-4 treatment enhanced T follicular helper-cell expansion in tumor-draining deep cervical lymph nodes, drove germinal-center B-cell maturation and IgG class switching, and generated glioma-reactive antibodies; antibody-secreting cells were required for therapeutic benefit, while the resulting IgG accumulated in tumors and promoted glioma-cell phagocytosis. CTLA-4 blockade therefore functions here not only by releasing antitumor T-cell activity but also by initiating a distal humoral response that is necessary for tumor control 42430444Jul.
Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4)
Gene: CTLA4 | Wikidata ID: Q2907609 | Category: Gene
Papers
The 19 papers from the last 6 months that study Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Cancer Immunotherapy (9)
- Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy. Science advances · 11 Sept 2026 PMID 42726873
- Anti-CTLA-4 antibody potentiates the antitumor effect of armed oncolytic virus OVM18 via enhancing intratumoral IL-18R1+CD8+ T cells. Journal for immunotherapy of cancer · 7 Sept 2026 PMID 42705862
- Iparomlimab and tuvonralimab in previously treated patients with cervical cancer. Cell reports. Medicine · 4 Aug 2026 PMID 42551432
- Discovery and development of small-molecule inhibitors targeting cytotoxic T lymphocyte associated protein 4 to enhance cancer immunotherapy and reduce side effects. International immunopharmacology · 31 Jul 2026 PMID 42537351
- Repurposed ethoxzolamide reprograms antitumor immunity through β-TrCP-dependent PD-L1 ubiquitination. Cell reports. Medicine · 13 Jul 2026 PMID 42442361
- The efficacy of immunotherapy in glioma requires distal B cell responses in tumor-draining lymph nodes. Science immunology · 10 Jul 2026 PMID 42430444
- Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones. Cancer research · 22 Jun 2026 PMID 42329854
- Transcriptomic profiling identifies immunotherapy-responsive phenotypes in microsatellite-stable metastatic colorectal cancer. Oncogene · 15 Jun 2026 PMID 42298180
- Vasoactive intestinal peptide associated 8-gene signature with prognostic and immune associations in melanoma. Medicine · 30 May 2026 PMID 42216340
Cytokine Cancer Immunotherapy (4)
- Identification of a circulating miR-6838-5p/miR-195-5p signature in invasive ductal breast carcinoma. Molecular biology reports · 16 Sept 2026 PMID 42747628
- Cytokines and chemokines in plasma as markers reflecting immunophenotype of head and neck squamous cell carcinoma. Human cell · 2 Sept 2026 PMID 42684559
- In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models. Cancer immunology research · 8 Jul 2026 PMID 42418729
- Integrating network pharmacology with ex-vivo analysis to assess the effect of IL-2 in halting breast cancer: involvement of Treg/CTLA-4/Blimp-1/caspase-3. Scientific reports · 26 May 2026 PMID 42192107
Checkpoint Toxicity and Safety (3)
- Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event. Immunologic research · 1 Jul 2026 PMID 42384108
- Checkpoint inhibitors create rogue regulatory T cells. The Journal of clinical investigation · 1 Jul 2026 PMID 42383349
- Engineering and Improving Anti-CTLA-4 Checkpoint Inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research · 8 Jun 2026 PMID 42258254
Others — Immune Regulation across Diseases (3)
- Virus-specific enhancement of the expression of CTLA-4 in T cells from target organs during early and late stages of PRRSV-1 infection with strains of different virulence. Veterinary microbiology · 2 Oct 2026 PMID 42826489
- Clinical Impact of CTLA4 and LAG3 Single-Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T-Cell Therapy. Hematological oncology · 29 Sept 2026 PMID 42806527
- Paradoxical Th1 activation and CTLA-4 regulation is beneficial during latent cryptococcosis. mBio · 22 Jul 2026 PMID 42484324
By study type
Clinical trials (1)
- Iparomlimab and tuvonralimab in previously treated patients with cervical cancer. Cell reports. Medicine · 4 Aug 2026 PMID 42551432
Observational studies and case reports (3)
- Clinical Impact of CTLA4 and LAG3 Single-Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T-Cell Therapy. Hematological oncology · 29 Sept 2026 PMID 42806527
- Identification of a circulating miR-6838-5p/miR-195-5p signature in invasive ductal breast carcinoma. Molecular biology reports · 16 Sept 2026 PMID 42747628
- Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event. Immunologic research · 1 Jul 2026 PMID 42384108
Human data, design not indexed (4)
- Cytokines and chemokines in plasma as markers reflecting immunophenotype of head and neck squamous cell carcinoma. Human cell · 2 Sept 2026 PMID 42684559
- Transcriptomic profiling identifies immunotherapy-responsive phenotypes in microsatellite-stable metastatic colorectal cancer. Oncogene · 15 Jun 2026 PMID 42298180
- Vasoactive intestinal peptide associated 8-gene signature with prognostic and immune associations in melanoma. Medicine · 30 May 2026 PMID 42216340
- Integrating network pharmacology with ex-vivo analysis to assess the effect of IL-2 in halting breast cancer: involvement of Treg/CTLA-4/Blimp-1/caspase-3. Scientific reports · 26 May 2026 PMID 42192107
Preclinical: animal, cell and lab studies (11)
- Virus-specific enhancement of the expression of CTLA-4 in T cells from target organs during early and late stages of PRRSV-1 infection with strains of different virulence. Veterinary microbiology · 2 Oct 2026 PMID 42826489
- Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy. Science advances · 11 Sept 2026 PMID 42726873
- Anti-CTLA-4 antibody potentiates the antitumor effect of armed oncolytic virus OVM18 via enhancing intratumoral IL-18R1+CD8+ T cells. Journal for immunotherapy of cancer · 7 Sept 2026 PMID 42705862
- Discovery and development of small-molecule inhibitors targeting cytotoxic T lymphocyte associated protein 4 to enhance cancer immunotherapy and reduce side effects. International immunopharmacology · 31 Jul 2026 PMID 42537351
- Paradoxical Th1 activation and CTLA-4 regulation is beneficial during latent cryptococcosis. mBio · 22 Jul 2026 PMID 42484324
- Repurposed ethoxzolamide reprograms antitumor immunity through β-TrCP-dependent PD-L1 ubiquitination. Cell reports. Medicine · 13 Jul 2026 PMID 42442361
- The efficacy of immunotherapy in glioma requires distal B cell responses in tumor-draining lymph nodes. Science immunology · 10 Jul 2026 PMID 42430444
- In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models. Cancer immunology research · 8 Jul 2026 PMID 42418729
- Checkpoint inhibitors create rogue regulatory T cells. The Journal of clinical investigation · 1 Jul 2026 PMID 42383349
- Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones. Cancer research · 22 Jun 2026 PMID 42329854
- Engineering and Improving Anti-CTLA-4 Checkpoint Inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research · 8 Jun 2026 PMID 42258254
Written from 19 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-18 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.